BCAB
BioAtla, Inc.
Price Chart
Latest Quote
$3.55
+0.10 (+2.90%)
Current Price
| Previous Close | $3.45 |
| Open | $3.43 |
| Day High | $3.61 |
| Day Low | $3.37 |
| Volume | 60,205 |
Stock Information
| Shares Outstanding | 1.66M |
| Total Debt | $6.09M |
| Cash Equivalents | $1.96M |
| Revenue | $2.00M |
| Net Income | $-50.62M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.89M |
| EPS (TTM) | $-41.56 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.85M |
| Sales | $2.00M |
| Income | $-50.62M |
| Book/sh | $-22.48 |
| Cash/sh | $1.18 |
| Employees | 41 |
Financial Ratios
| Quick Ratio | 0.10 |
| Current Ratio | 0.15 |
Returns & Margins
| ROA | -134.45% |
| Operating Margin | -2519.95% |
Ownership
| Insider Ownership | 5.46% |
| Institutional Ownership | 23.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.66 |
| P/S | 2.95 |
| P/B | -0.16 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.61 |
| SMA50 | $4.19 |
| SMA200 | $20.63 |
| RSI | 38.43 |
| ATR | 0.3284 |
| Shares Float | 1.38M |
| Short Float | 9.19% |
| Short Ratio | 4.35 |
| Rel Volume | 1.06 |
Performance History
| Week | -2.74% |
| Month | -9.44% |
| Quarter | -55.63% |
| 6 Months | -90.80% |
| YTD | -86.70% |
| Year | -82.25% |
| 3 Years | -98.11% |
| 5 Years | -99.86% |
| 10 Years | -99.77% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $3.55 | 60,205 |
| 2026-06-16 | $3.45 | 33,300 |
| 2026-06-15 | $3.62 | 97,700 |
| 2026-06-12 | $3.86 | 77,800 |
| 2026-06-11 | $3.56 | 14,300 |
| 2026-06-10 | $3.65 | 39,000 |
| 2026-06-09 | $3.44 | 54,000 |
| 2026-06-08 | $3.31 | 54,700 |
| 2026-06-05 | $3.33 | 113,200 |
| 2026-06-04 | $3.49 | 252,200 |
| 2026-06-03 | $3.40 | 24,100 |
| 2026-06-02 | $3.53 | 22,200 |
| 2026-06-01 | $3.53 | 34,300 |
| 2026-05-29 | $3.93 | 33,700 |
| 2026-05-28 | $4.05 | 109,500 |
| 2026-05-27 | $3.73 | 19,100 |
| 2026-05-26 | $3.91 | 28,500 |
| 2026-05-22 | $3.69 | 16,900 |
| 2026-05-21 | $3.62 | 26,400 |
| 2026-05-20 | $3.62 | 29,000 |
| 2026-05-19 | $3.87 | 82,800 |
| 2026-05-18 | $3.92 | 37,400 |
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,000,000 | $11,000,000 | $0 | $0 |
| Operating Revenue | $2,000,000 | $11,000,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $61,305,000 | $84,943,000 | $129,687,000 | $108,140,000 |
| Other Income Expense | $-1,145,000 | $798,000 | $-87,000 | $10,000 |
| Other Non Operating Income Expenses | $-1,440,000 | $-9,000 | $-87,000 | $10,000 |
| Net Non Operating Interest Income Expense | $843,000 | $3,369,000 | $6,312,000 | $1,648,000 |
| Operating Expense | $61,305,000 | $84,943,000 | $129,687,000 | $108,140,000 |
| General And Administrative Expense | $17,732,000 | $21,848,000 | $25,956,000 | $28,793,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Net Interest Income | $843,000 | $3,369,000 | $6,312,000 | $1,648,000 |
| Interest Income | $843,000 | $3,369,000 | $6,312,000 | $1,648,000 |
| Normalized Income | $-59,902,000 | $-70,583,000 | $-123,462,000 | $-106,482,000 |
| Net Income From Continuing And Discontinued Operation | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Total Operating Income As Reported | $-59,305,000 | $-73,943,000 | $-129,687,000 | $-108,140,000 |
| Net Income Common Stockholders | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Net Income | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Net Income Including Noncontrolling Interests | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Net Income Continuous Operations | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Pretax Income | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Interest Income Non Operating | $843,000 | $3,369,000 | $6,312,000 | $1,648,000 |
| Operating Income | $-59,305,000 | $-73,943,000 | $-129,687,000 | $-108,140,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-50.50 | $-60.05 | $-129.00 | $-49.79 |
| Basic EPS | $-50.50 | $-60.05 | $-129.00 | $-49.79 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-59,227,000 | $-73,825,000 | $-128,466,000 | $-106,941,000 |
| Total Unusual Items | $295,000 | $807,000 | - | $0 |
| Total Unusual Items Excluding Goodwill | $295,000 | $807,000 | - | $0 |
| Reconciled Depreciation | $373,000 | $925,000 | $1,221,000 | $1,199,000 |
| EBITDA (Bullshit earnings) | $-58,932,000 | $-73,018,000 | $-128,466,000 | $-106,941,000 |
| EBIT | $-59,305,000 | $-73,943,000 | $-129,687,000 | $-108,140,000 |
| Diluted Average Shares | $1,176,558 | $1,161,983 | $955,551 | $2,138,682 |
| Basic Average Shares | $1,176,558 | $1,161,983 | $955,551 | $2,138,682 |
| Diluted NI Availto Com Stockholders | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Gain On Sale Of Security | $295,000 | $807,000 | - | - |
| Research And Development | $43,573,000 | $63,095,000 | $103,731,000 | $79,347,000 |
| Selling General And Administration | $17,732,000 | $21,848,000 | $25,956,000 | $28,793,000 |
| Other Gand A | $17,732,000 | $21,848,000 | $25,956,000 | $28,793,000 |
| Minority Interests | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Total Assets | $13,828,000 | $52,422,000 | $119,658,000 | $225,736,000 |
| Total Non Current Assets | $5,815,000 | $1,190,000 | $3,252,000 | $5,305,000 |
| Other Non Current Assets | $163,000 | - | $154,000 | $154,000 |
| Current Assets | $8,013,000 | $51,232,000 | $116,406,000 | $220,431,000 |
| Other Current Assets | $232,000 | $447,000 | $320,000 | $539,000 |
| Prepaid Assets | $663,000 | $1,739,000 | $4,615,000 | $4,385,000 |
| Cash Cash Equivalents And Short Term Investments | $7,118,000 | $49,046,000 | $111,471,000 | $215,507,000 |
| Cash And Cash Equivalents | $7,118,000 | $49,046,000 | $111,471,000 | $215,507,000 |
| Debt | ||||
| Total Debt | $6,200,000 | $836,000 | $2,460,000 | $3,981,000 |
| Long Term Debt And Capital Lease Obligation | $4,773,000 | $0 | $836,000 | $2,460,000 |
| Current Debt And Capital Lease Obligation | $1,427,000 | $836,000 | $1,624,000 | $1,521,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $50,017,000 | $38,157,000 | $48,986,000 | $45,397,000 |
| Total Non Current Liabilities Net Minority Interest | $28,095,000 | $23,617,000 | $20,642,000 | $22,266,000 |
| Other Non Current Liabilities | $19,806,000 | $19,806,000 | $19,806,000 | $19,806,000 |
| Derivative Product Liabilities | $3,516,000 | $3,811,000 | $0 | - |
| Current Liabilities | $21,922,000 | $14,540,000 | $28,344,000 | $23,131,000 |
| Current Deferred Liabilities | $4,142,000 | $0 | - | - |
| Payables And Accrued Expenses | $16,316,000 | $10,978,000 | $22,930,000 | $18,159,000 |
| Payables | $8,194,000 | $1,902,000 | $3,819,000 | $4,231,000 |
| Accounts Payable | $8,194,000 | $1,902,000 | $3,819,000 | $4,231,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Total Equity Gross Minority Interest | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Stockholders Equity | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Retained Earnings | $-545,646,000 | $-486,039,000 | $-416,263,000 | $-292,801,000 |
| Other | ||||
| Ordinary Shares Number | $1,269,286 | $1,161,983 | $961,551 | $2,138,682 |
| Share Issued | $1,269,286 | $1,161,983 | $961,551 | $2,138,682 |
| Tangible Book Value | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Invested Capital | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Working Capital | $-13,909,000 | $36,692,000 | $88,062,000 | $197,300,000 |
| Capital Lease Obligations | $6,200,000 | $836,000 | $2,460,000 | $3,981,000 |
| Total Capitalization | $-36,189,000 | $14,265,000 | $70,672,000 | $180,339,000 |
| Additional Paid In Capital | $509,451,000 | $500,298,000 | $486,930,000 | $473,135,000 |
| Capital Stock | $6,000 | $6,000 | $5,000 | $5,000 |
| Common Stock | $6,000 | $6,000 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $4,773,000 | $0 | $836,000 | $2,460,000 |
| Current Capital Lease Obligation | $1,427,000 | $836,000 | $1,624,000 | $1,521,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,000 | $2,726,000 | $3,790,000 | $3,451,000 |
| Current Accrued Expenses | $8,122,000 | $9,076,000 | $19,111,000 | $13,928,000 |
| Net PPE | $5,652,000 | $1,190,000 | $3,098,000 | $5,151,000 |
| Accumulated Depreciation | $-5,308,000 | $-7,003,000 | $-6,078,000 | $-5,364,000 |
| Gross PPE | $10,960,000 | $8,193,000 | $9,176,000 | $10,515,000 |
| Leases | $2,498,000 | $3,680,000 | $3,680,000 | $3,687,000 |
| Other Properties | $7,361,000 | $2,792,000 | $3,775,000 | $4,688,000 |
| Machinery Furniture Equipment | $1,101,000 | $1,721,000 | $1,721,000 | $2,140,000 |
| Properties | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-48,204,000 | $-71,936,000 | $-104,113,000 | $-90,688,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-48,204,000 | $-71,936,000 | $-104,015,000 | $-90,420,000 |
| Cash Flow From Continuing Operating Activities | $-48,204,000 | $-71,936,000 | $-104,015,000 | $-90,420,000 |
| Operating Gains Losses | $-110,000 | $-807,000 | $2,000 | $13,000 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-98,000 | $-265,000 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-98,000 | $-265,000 |
| Capital Expenditure | - | - | $-98,000 | $-268,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $9,215,000 | $0 | $61,682,000 |
| Financing Cash Flow | $6,276,000 | $9,511,000 | $77,000 | $61,213,000 |
| Cash Flow From Continuing Financing Activities | $6,276,000 | $9,511,000 | $77,000 | $61,213,000 |
| Net Other Financing Charges | $-949,000 | $-46,000 | $-259,000 | $-758,000 |
| Net Common Stock Issuance | $0 | $9,215,000 | $0 | $61,682,000 |
| Common Stock Issuance | $0 | $9,215,000 | $0 | $61,682,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $7,125,000 | $0 | - | - |
| End Cash Position | $7,118,000 | $49,046,000 | $111,471,000 | $215,507,000 |
| Beginning Cash Position | $49,046,000 | $111,471,000 | $215,507,000 | $244,979,000 |
| Changes In Cash | $-41,928,000 | $-62,425,000 | $-104,036,000 | $-29,472,000 |
| Proceeds From Stock Option Exercised | $100,000 | $342,000 | $336,000 | $289,000 |
| Net Issuance Payments Of Debt | $7,125,000 | $0 | - | - |
| Net Long Term Debt Issuance | $7,125,000 | $0 | - | - |
| Long Term Debt Issuance | $7,125,000 | $0 | - | - |
| Change In Working Capital | $4,276,000 | $-11,199,000 | $4,680,000 | $287,000 |
| Change In Other Working Capital | $344,000 | $-641,000 | $-593,000 | $-513,000 |
| Change In Payables And Accrued Expense | $2,804,000 | $-13,461,000 | $5,284,000 | $3,411,000 |
| Change In Prepaid Assets | $1,128,000 | $2,903,000 | $-11,000 | $-2,611,000 |
| Other Non Cash Items | $1,024,000 | - | - | - |
| Stock Based Compensation | $5,434,000 | $8,921,000 | $13,544,000 | $14,563,000 |
| Unrealized Gain Loss On Investment Securities | $406,000 | $0 | - | - |
| Depreciation Amortization Depletion | $373,000 | $925,000 | $1,221,000 | $1,199,000 |
| Depreciation And Amortization | $373,000 | $925,000 | $1,221,000 | $1,199,000 |
| Gain Loss On Investment Securities | $-295,000 | $-807,000 | - | - |
| Gain Loss On Sale Of PPE | $185,000 | $0 | $2,000 | $13,000 |
| Net Income From Continuing Operations | $-59,607,000 | $-69,776,000 | $-123,462,000 | $-106,482,000 |
| Income Tax Paid Supplemental Data | - | $0 | $6,000 | $67,000 |
| Net PPE Purchase And Sale | - | $0 | $-98,000 | $-265,000 |
| Purchase Of PPE | - | $0 | $-98,000 | $-268,000 |
| Sale Of PPE | - | - | $0 | $3,000 |
| Change In Payable | - | - | $5,284,000 | $3,411,000 |
| Change In Account Payable | - | - | $5,284,000 | $3,411,000 |
Fetched: 2026-06-16